Imaging agent developer ImaginAb has formed a strategic partnership with Canadian radioisotope production technology developer ARTMS Products.
Under the multiyear, nonexclusive deal, the two firms said they will explore radiochemistry manufacturing of ImaginAB's lead CD8 ImmunoPet T-cell PET imaging agent. ImaginAb believes that this manufacturing methodology would enable an increase in zirconium-89 supply and offer the potential to expand ImaginAb's supply sites. In addition, it could also be applied to other agents in ImaginAb's product pipeline, the companies said.
ARTMS will perform pilot and optimization studies to assess the radiolabeling of the CD8 ImmunoPET minibody with this new methodology, according to the vendors.
